BIOMAT Database Logo BIOMAT Database Logo

Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors. 1997

J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano

UI MeSH Term Description Entries
D008297 Male Males
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
November 1999, Journal of acquired immune deficiency syndromes (1999),
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Hyperglycemia associated with protease inhibitors in HIV-1-infected patients.
July 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
January 2003, HIV medicine,
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.
November 2000, AIDS (London, England),
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Lipid and glucose metabolism in HIV-1-infected children treated with protease inhibitors.
January 2002, Archives of disease in childhood,
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
August 2001, AIDS research and human retroviruses,
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
May 2003, AIDS patient care and STDs,
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
February 2001, Lancet (London, England),
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Lipid evaluation in HIV-1-positive patients treated with protease inhibitors.
January 1999, Antiviral therapy,
J Mallolas, and J Arrizabalaga, and M Loncá, and J M Gatell, and A Adán, and E Martínez-Chamorro, and C Tortajada, and F Rodríguez-Arrondo, and A Blanco, and A Guelar, and E Soriano
Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.
October 2000, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!